FY2025 EPS Forecast for NeuroPace Increased by Analyst

Key Points

• Analysts from Leerink Partners have raised their earnings per share (EPS) forecast for NeuroPace, predicting a loss of ($0.80) for FY2025, improved from a previous estimate of ($0.83).
• NeuroPace reported a quarterly loss of ($0.26) per share, which fell short of the analysts' expectations of ($0.24), despite generating revenue of $23.52 million which exceeded forecasts.
• Five analyst firms currently rate NeuroPace as a "buy," with an average target price of $16.60, highlighting a generally positive outlook from the investment community.

NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Research analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for NeuroPace in a research note issued to investors on Tuesday, August 12th. Leerink Partnrs analyst M. Kratky now expects that the company will earn ($0.80) per share for the year, up from their prior forecast of ($0.83). The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's Q4 2025 earnings at ($0.14) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.28 EPS.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $23.52 million during the quarter, compared to the consensus estimate of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%.

A number of other equities research analysts also recently issued reports on NPCE. JPMorgan Chase & Co. upped their price objective on NeuroPace from $14.00 to $16.00 and gave the company an "overweight" rating in a research report on Wednesday, May 14th. Wells Fargo & Company dropped their price objective on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday. HC Wainwright assumed coverage on NeuroPace in a research report on Wednesday, May 28th. They set a "buy" rating and a $18.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a research report on Wednesday, May 14th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $16.60.

NeuroPace Price Performance

Shares of NASDAQ:NPCE traded up $0.10 during mid-day trading on Friday, reaching $9.13. The stock had a trading volume of 18,223 shares, compared to its average volume of 274,604. The company has a current ratio of 5.47, a quick ratio of 5.70 and a debt-to-equity ratio of 3.02. The company has a market cap of $301.86 million, a P/E ratio of -10.81 and a beta of 1.89. NeuroPace has a 1 year low of $5.45 and a 1 year high of $18.98. The business's 50 day moving average price is $10.00 and its 200 day moving average price is $11.78.

Hedge Funds Weigh In On NeuroPace

A number of institutional investors have recently modified their holdings of NPCE. Ameritas Investment Partners Inc. increased its stake in shares of NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock valued at $27,000 after purchasing an additional 1,118 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of NeuroPace in the 4th quarter valued at about $29,000. Legal & General Group Plc boosted its holdings in NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock worth $30,000 after buying an additional 1,239 shares during the last quarter. Quantbot Technologies LP acquired a new stake in NeuroPace in the 2nd quarter worth about $35,000. Finally, GAMMA Investing LLC acquired a new stake in NeuroPace in the 1st quarter worth about $53,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.